Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA (AZN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

AstraZeneca : 3Q Operating Profit Rises Despite Product Sales Decline

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/09/2017 | 08:55am CEST

By Adam Clark

AstraZeneca PLC (AZN.LN) reported Thursday that its operating profit for the third quarter of 2017 increased, boosted by a one-off tax benefit, but product sales continued to decline due to the loss of exclusivity on some key drugs.

The pharmaceutical company's operating profit rose 12% to $1.15 billion, up 9% in constant currencies. Pretax profit rose 33% to $1.82 billion.

However, product sales for the quarter fell 3% to $4.88 billion, which AstraZeneca said was due to a loss of exclusivity on its Crestor and Seroquel products. Total revenue rose 9% to $6.23 billion, benefiting from a contribution from externalization revenue--proceeds from partnerships and licensing deals.

AstraZeneca narrowed its 2017 guidance, saying it now expects its core earnings per share to be towards the favorable end of a low to mid-teens percentage decline. It reiterated its 2017 revenue guidance of a low to mid single-digit percentage drop.

Chief Executive Pascal Soriot said the most notable developments of the quarter were positive data from the company's drugs pipeline, especially its Tagrisso and Imfinzi cancer therapy candidates.

Write to Adam Clark at [email protected]; @AdamDowJones

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
04/24ASTRAZENECA : raises stake in respiratory partner Circassia
RE
04/24Circassia 2017 Pretax Loss Narrows; AstraZeneca Increases Stake
DJ
04/24ASTRAZENECA : Negative Results From Phase 3 Trial of Imfinzi and Tremelimumab
DJ
04/24ASTRAZENECA : reports results from the ARCTIC trial in third-line non-small cell..
PU
04/24ASTRAZENECA : high level results of the ARCTIC trial
AQ
04/23China to scrap import tariffs on 28 drugs
AQ
04/23China to scrap import tariffs on 28 drugs
AQ
04/22ASTRAZENECA : Highmark Inc. Signs Outcomes-based Agreement With AstraZeneca for ..
AQ
04/21ASTRAZENECA : AZ`s Tagrisso gets FDA nod in first-line EGFR-mutated lung cancer
AQ
04/19RESEARCHERS AT ASTRAZENECA HAVE REPO : ...
AQ
More news
News from SeekingAlpha
04/24BY THE NUMBERS : Healthcare Stocks With Big Cash Distributions 
04/24ROUNDS REPORT : Eleven Train Took Off While Improved FDA Policy Favors Infectiou.. 
04/23ELEVEN BIOTHERAPEUTICS : An Assessment Of A Potential Big Winner 
04/213 THINGS IN BIOTECH, APRIL 20 : AstraZeneca Re-Enters The Big Leagues, Aduro Loo.. 
04/203 THINGS IN BIOTECH, APRIL 19 : Let's Talk Genito-Urinary Cancer 
Financials ($)
Sales 2018 22 562 M
EBIT 2018 5 532 M
Net income 2018 1 887 M
Debt 2018 14 767 M
Yield 2018 4,00%
P/E ratio 2018 38,12
P/E ratio 2019 29,10
EV / Sales 2018 4,57x
EV / Sales 2019 4,32x
Capitalization 88 255 M
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 75,5 $
Spread / Average Target 8,0%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA-2.83%88 255
JOHNSON & JOHNSON-9.35%339 783
PFIZER1.13%217 897
NOVARTIS-7.72%204 972
ROCHE HOLDING LTD.-11.72%192 109
MERCK AND COMPANY7.07%158 571